કૃષ્ણા ડાયગ્નોસ્ટિક્સ શેર પ્રાઇસ

Earnings Call Recording for Quarter ended June 30, 2026

• BSE ઇન્ડિયા
• 2 કલાક 53 મિનિટ પહેલાં

<h3><span style="font-size:16px;"><strong>Healthcare Services company Krsnaa Diagnostics announced Q1FY27 results</strong></span></h3><p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">કન્સોલિડેટેડ ફાઇનાન્શિયલ હાઇલાઇટ્સ:</strong></p><ul><li _ngcontent-ng-c1940132427="">Revenue from operations for Q1FY27 stood at Rs 2,355.32 million, representing a YoY growth of 22.05% from Rs 1,929.78 million in Q1FY26 and a QoQ growth of 22.29% from Rs 1,926.04 million in Q4FY26.</li><li _ngcontent-ng-c1940132427="">Total income in Q1FY27 was Rs 2,427.72 million, up 23.28% YoY from Rs 1,969.28 million in Q1FY26 and up 8.33% QoQ from Rs 2,241.03 million in Q4FY26.</li><li _ngcontent-ng-c1940132427="">Profit before tax (PBT) for Q1FY27 reached Rs 224.36 million, a decrease of 18.18% YoY compared to Rs 274.22 million in Q1FY26 and a decline of 56.60% QoQ compared to Rs 517.01 million in Q4FY26.</li><li _ngcontent-ng-c1940132427="">Net profit (Profit for the period) for Q1FY27 was Rs 165.51 million, showing a YoY decline of 19.34% from Rs 205.20 million in Q1FY26 and a QoQ decline of 60.33% from Rs 417.18 million in Q4FY26.</li><li _ngcontent-ng-c1940132427="">Basic EPS for Q1FY27 stood at Rs 5.10, as against Rs 6.35 in Q1FY26 and Rs 12.86 in Q4FY26.</li></ul><p><strong _ngcontent-ng-c1940132427="">સ્ટેન્ડઅલોન ફાઇનાન્શિયલ હાઇલાઇટ્સ:</strong></p><ul><li _ngcontent-ng-c1940132427="">Revenue from operations for Q1FY27 was Rs 2,106.61 million, a growth of 19.96% YoY from Rs 1,756.15 million in Q1FY26 and 21.76% growth QoQ from Rs 1,730.18 million in Q4FY26.</li><li _ngcontent-ng-c1940132427="">Total income for Q1FY27 reached Rs 2,178.70 million, an increase of 21.30% YoY from Rs 1,796.13 million in Q1FY26 and an increase of 6.58% QoQ from Rs 2,044.24 million in Q4FY26.</li><li _ngcontent-ng-c1940132427="">Profit before tax (PBT) for Q1FY27 was Rs 215.16 million, down 18.31% YoY from Rs 263.37 million in Q1FY26 and down 60.25% QoQ from Rs 541.32 million in Q4FY26.</li><li _ngcontent-ng-c1940132427="">Net profit for Q1FY27 was Rs 158.20 million, representing a YoY decrease of 19.13% from Rs 195.62 million in Q1FY26 and a 63.53% decrease QoQ from Rs 433.82 million in Q4FY26.</li></ul><p><strong _ngcontent-ng-c1940132427="">બિઝનેસ હાઇલાઇટ્સ:</strong></p><ul><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Segment Performance:</strong> The Group operates as a single operating segment providing diagnostic services in radiology and pathology. Revenue is entirely derived from external customers in India, with entire assets located within the country.</li><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Issuance of Share Warrants:</strong> The Board approved the issuance of 16,21,000 share warrants on a preferential basis to promoters (Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited). The issue price is to be determined in the future, with a minimum floor price of Rs 565/- per warrant.</li><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Dividend:</strong> A final dividend of Rs 2.00/- per share has been recommended for the financial year 2024-25. The record date for the payment is Friday, September 18, 2026.</li><li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Income Tax Demand Update:</strong> Following search and seizure operations, the company received demand orders totaling Rs 626.90 million. The company has filed appeals and deposited Rs 102.77 million under protest (including cash payments and request for adjustment of refunds). Management maintains that these demand orders are not tenable and expects no material impact on financial performance.</li></ul><p><strong>Yash Mutha, Managing Director, said</strong>: “Q1 FY2027 reflects the growing strength of the platform we have built. Our existing business continues to grow, while Rajasthan and other new projects are adding a second layer of growth. With retail scaling rapidly and our newly commissioned infrastructure moving towards higher utilisation, we remain focused on converting the platform we have built into sustainable, long-term value for our shareholders.”</p><p><strong>Mitesh Dave, Group Chief Executive Officer, said:</strong> “Q1 was a quarter of execution converting infrastructure into live, revenue-generating capacity. Rajasthan is now operational, our retail network has crossed 4000 + touchpoints and our radiology footprint continues to expand. As utilisation builds across these investments, we expect the operating leverage inherent in our model to become increasingly visible.”</p><p><a class="lb" href="/gujarati/get-document/post/pdf/5790591/" target="_blank">પરિણામની PDF</a></p>

• ટ્રેન્ડલાઇન
• 7 કલાક 34 મિનિટ પહેલાં

ઇન્વેસ્ટર પ્રેઝન્ટેશન

• BSE ઇન્ડિયા
• 20 કલાક 9 મિનિટ પહેલાં